VIAV programme - Links - Programme EVA - Summary - Technology Transfer Office
Home


Home
AVIP in few words
Background
Mission
Projects and Plans
Participants
EVA Program
Tech Transf
VIAV programme
Summary
Contact Us
Press Room
Links

Username
Password

VIAV programme PDF Print E-mail
Very Innovative AIDS Vaccine
Written by Administrator   

The goal of the VIAV programme is to develop a novel, broadly effective HIV/AIDS vaccine based on HIV Tat and Env protein complexes. VIAV is built upon an international consortium of European experts in the fields of HIV/AIDS protein structure and molecular modelling/docking, biochemistry, molecular biology, virology, immunology, vaccine development, GMP production, trial conduction and field studies.

Background: Results obtained by the VIAV Consortium indicate that the HIV Tat protein increases HIV cell adsorption, infectivity and tropisms by interacting with components of the HIV membrane and envelope protein (Env). Because the interaction between Tat and Env may allow the generation of complex-specific, neutralisation-sensitive epitopes and/or the stabilisation of cryptic and/or transiently exposed Env epitopes, a vaccine based on Tat-Env complexes is likely to generate protective immune responses against vulnerable viral targets.

Aim: The aim of VIAV is to develop a highly innovative Tat-Env complex-based vaccine capable of inducing cross-clade neutralising antibodies against novel, neutralisation-sensitive Env epitopes to prevent HIV infection and/or AIDS progression. The VIAV aim will be achieved through new antigen design stemming out from novel virological, immunological and modeling data of the VIAV Consortium.

Expected results: The VIAV project will allow the identification of novel HIV/AIDS vaccine immunogens and formulations for the induction of broad immunity against HIV. Tat-Env complexes will be characterised and used to immunise small animals, where vaccination is expected to be safe and immunogenic. Neutralising antibody responses will be also characterised and novel neutralisation-sensitive, complex-induced epitopes will be identified.

Potential applications: The VIAV programme will bring specific contributions to AIDS vaccine research and development in terms of innovative vaccine formulations. In particular, the exploitation of novel vaccine formulations based on newly-identified/produced protein complexes that are potentially relevant in the context of HIV natural infection may directly result from VIAV. VIAV is an ambitious project that will fit in the scientific effort aimed at developing innovative AIDS candidate vaccines, based on combinations of regulatory and structural viral proteins. VIAV is also linked to the AIDS Vaccine Integrated Project (AVIP), recently awarded by the EU Commission, for future product development and clinical testing.

Coordinator: Flavia Ferrantelli National AIDS Center
Istituto Superiore di Sanità

Viale Regina Elena 299 00161 Rome Italy

 Tel: +39 06 4990 3209 Fax: +39 06 4990 3002

E-mail: flaviafr@iss.it Website: http://www.iss.it

Partners

N.

Principal
Scientific
Participants

Official Address

Other Information

1

Flavia Ferrantelli

National AIDS Center
Istituto Superiore di Sanità

Viale Regina Elena 299
00161 Rome
Italy

Tel: +39 06 4990 3209
Fax: +39 06 4990 3002
E-mail: flaviafr@iss.it
Website: http://www.iss.it

2

Banci Lucia

Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine
Paramagnetiche
Via L. Sacconi 6
IT-50019 Sesto Fiorentino
Italy

Tel: +39 055 457 4263
Fax: +39 055 457 4253
E-mail: banci@cerm.unifi.it
Website: http://www.cerm.unifi.it

3

Eva Maria Fenyo

Lunds Universitet
Solvegatan 23
SE-22362 Lund
Sweden

Tel: +46 46 17 3275
Fax: +46 46 17 6033
E-mail: Eva_maria.fenyo@mmb.lu.se
Website: http://www.lu.se

4

Dag Helland

Universitetet I Bergen
Museplass 1
5020 Bergen
Norway

Tel: +47 55 58 45 19
Fax: +47 55 58 96 83
E-mail: dag.helland@mbi.uib.no
Website: http://www.uib.no

5

Elisa Gargiulo

DIATHEVA srl
Viale Piceno 137/F
IT-61032 Fano
Italy

Tel: +39 0721 830 605
Fax: +39 0721 837 154
E-mail: r&d@diatheva.com
Website: http://www.diatheva.com

6

Mauro Magnani

University of Urbino 
Institute of Biological Chemistry 'G. Fornaini' Via Saffi, 2
IT-61029 Urbino
Italy

Tel: +39 0722 305211
Fax: +39 0722 320188
E-mail: magnani@uniurb.it

7

Antonella Caputo

University of Padova
Department of Histology, Microbiology, and Medical Biotechnology
Via A. Gabelli 63
IT- 35122   Padova
Italy

 

Tel: +39 049 8272340
Fax: +39 049 8272355
E-mail: mcpa@dns.unife.it

8

Riccardo Gavioli

University of Ferrara 
Laboratory of Cellular and Molecular Oncology, Department of Biochemestry and molecular Biology
Via Fossato di Mortara, 74
IT-44100  Ferrara
Italy

 

Tel : +39  0532 424407
Fax: +39 0532 424484
E-mail: r.gavioli@unife.it


 
European Commission Help Help Credits Credits Legal Notice Legal Notice